4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial

4D Molecular (FDMT) Therapeutics announced positive interim clinical data from the 4D-710 Phase 1 AEROW clinical trial for the treatment of cystic fibrosis lung disease. AEROW Phase 1 Interim Data: No new pulmonary or other safety events occurred since previous update in higher-dose cohorts with up to 3.5 years of follow-up; In lower-dose cohorts, 4D-710-related adverse events were generally mild, transient and resolved by 2 months, with no 4D-710-related severe adverse events; Airway biopsy and brushing results demonstrated consistent and dose-dependent CFTR transgene RNA levels at or above physiologically relevant levels in non-CF control samples. In 2.5E14 vg dose cohort, results met target expression profile In 2.5E14 vg dose cohort, consistent evidence of clinically meaningful activity detected in all endpoints, including ppFEV1, LCI2.5 and quality of life through 1 year; Based on evaluation of safety, tissue expression and efficacy data, 2.5E14 vg was selected as the Phase 2 dose